Interferon Gamma-1b (Actimmune) - Early Termination of Trial for Idiopathic Pulmonary Fibrosis
March 9, 2007
The INSPIRE trial evaluating interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis was terminated early due to lack of benefit. In an interim analysis, more patient died who were treated with interferon gamma-1b (14.5%) compared to patients treated with placebo (12.7%).
Additional information can be obtained at the following links:
- MedWatch Alert:
- Public Health Advisory:
- Drug Information Page:
March 9, 2007; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.